tezacaftor: Clinical Trials

21 trials of tezacaftor, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

18 completed, 2 recruiting, 1 unknown. 9 Phase 2, 7 Phase 1, 4 Phase 3, 1 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 29Completed 9
Phase 17Completed 5, Recruiting 2
Phase 34Completed 4
Phase 41Completed 1

Follow tezacaftor: new trials by email Literature Review of tezacaftor trials Research Report on tezacaftor

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants
VX-272, Placebo, Tezacaftor - Cystic Fibrosis
Phase 1RecruitingVertex Pharmaceuticals Incorporated1602026-02-252026-09-23
Evaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis
VX-581, Placebo, D-IVA - Cystic Fibrosis
Phase 1RecruitingVertex Pharmaceuticals Incorporated1522025-12-092026-10-19
Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis
VX-828, Placebo, Itraconazole - Cystic Fibrosis
Phase 1CompletedVertex Pharmaceuticals Incorporated1652023-12-122026-08-10
Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis
Trikafta - Non-cystic Fibrosis Bronchiectasis
Phase 4CompletedEmory University322023-04-182026-02-09
Daily Monitoring of Respiratory Symptoms and Spirometry During ETI Treatment in Persons With Cystic Fibrosis.
Elexacaftor 100 MG / Ivacaftor 75 MG / Tezacaftor 50 MG, 2 tablets each morning + Ivacaftor 150 mg one tablet each evening - Cystic Fibrosis
UnknownCHC Montlegia202022-09-012022-10-31
Trikafta in Cystic Fibrosis Patients
Trikafta - Cystic Fibrosis
Phase 2CompletedEmory University422019-09-042026-08-11
Gut Imaging for Function & Transit in Cystic Fibrosis Study 2
Tezacaftor/Ivacaftor + Ivacaftor, Placebo oral tablet - Cystic Fibrosis
Phase 2CompletedNottingham University Hospitals NHS Trust122019-09-032023-05-24
A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis
VX-121, TEZ, VX-561 - Cystic Fibrosis
Phase 2CompletedVertex Pharmaceuticals Incorporated872019-04-302023-04-20
A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis
TEZ/IVA, IVA, Placebo - Cystic Fibrosis
Phase 3CompletedVertex Pharmaceuticals Incorporated672018-05-172020-02-11
A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis
VX-659, TEZ/IVA, IVA - Cystic Fibrosis
Phase 2CompletedVertex Pharmaceuticals Incorporated1242017-08-082021-04-22
A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis
IVA, TEZ/IVA, VX-445 - Cystic Fibrosis
Phase 1 / Phase 2CompletedVertex Pharmaceuticals Incorporated2252017-01-232022-01-18
A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis
VX-659, Tezacaftor, Ivacaftor - Cystic Fibrosis
Phase 1CompletedVertex Pharmaceuticals Incorporated1632016-11-012017-09-05
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)
TEZ, TEZ/IVA, IVA - Cystic Fibrosis
Phase 3CompletedVertex Pharmaceuticals Incorporated832016-11-012020-03-04
A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis
TEZ, IVA, VX-440 - Cystic Fibrosis
Phase 2CompletedVertex Pharmaceuticals Incorporated742016-10-012020-08-28
A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy Adult Subjects
VX-440, TEZ, IVA - Cystic Fibrosis
Phase 1CompletedVertex Pharmaceuticals Incorporated162016-07-202018-04-03
A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Tezacaftor/Ivacaftor, Ivacaftor, Tezacaftor/Ivacaftor matching placebo - Cystic Fibrosis
Phase 2CompletedVertex Pharmaceuticals Incorporated342016-02-012021-07-19
A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation
VX-661 plus ivacaftor combination, Ivacaftor, Placebo (matched to VX-661 plus ivacaftor combination) - Cystic Fibrosis
Phase 3CompletedVertex Pharmaceuticals Incorporated1682015-08-012018-06-12
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor
VX-661 Plus Ivacaftor Combination, Ivacaftor, VX-661 Plus Ivacaftor Combination Placebo - Cystic Fibrosis
Phase 3CompletedVertex Pharmaceuticals Incorporated5102015-01-012018-06-12
Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion
VX-661, Ivacaftor, Placebo matched to VX-661 - Cystic Fibrosis
Phase 2CompletedVertex Pharmaceuticals Incorporated402014-03-012025-09-24
An Open-Label, Phase 1 Study in Healthy Adult Subjects to Examine the Effects of Multiple-Dose Ciprofloxacin on Ivacaftor and VX-661 in Combination With Ivacaftor
ivacaftor, VX-661, ciprofloxacin - Cystic Fibrosis
Phase 1CompletedVertex Pharmaceuticals Incorporated342014-01-012014-03-26

Showing 20 of 21. Sign in to see all of them.

Conditions studied

Cystic Fibrosis (20)  ·  Signs and Symptoms, Respiratory (1)

Sponsors

Vertex Pharmaceuticals Incorporated (17)  ·  Emory University (2)  ·  CHC Montlegia (1)  ·  Nottingham University Hospitals NHS Trust (1)

Countries

United States (15)  ·  United Kingdom (9)  ·  Canada (5)  ·  Germany (5)  ·  Australia (4)  ·  Belgium (4)  ·  Denmark (3)  ·  France (3)  ·  Ireland (3)  ·  Netherlands (3)  ·  Spain (3)  ·  Austria (2)  ·  Israel (2)  ·  Italy (2)  ·  Switzerland (2)

Top investigators

Eric Sorscher, MD (2)  ·  Alan Smyth, Prof (1)  ·  Giles Major, Dr (1)  ·  Patrick Lebecque, PhD (1)  ·  Scott Donaldson, MD (1)

Results publications

PMID 33331662, PMID 37983082, PMID 30334693, PMID 29099344, PMID 30334692, PMID 31253540, PMID 32546431, PMID 36509366, PMID 36842446, PMID 39139270, PMID 39208836, PMID 39951444, PMID 42271629

NIH funding

2016 (5), 2017 (2), 2014 (1), R01HL139876 (1)